Inspire Medical (NYSE:INSP) today posted second-quarter results that came in ahead of the consensus Wall Street forecast.
The company also announced a new strategic growth plan aimed at creating additional investment capacity to accelerate revenue growth. It calls the plan “Project Horizon.”
Shares of INSP rose more than 13% to $59.18 apiece in post-market trading today. It comes as a welcome boost for the company, which faced a sell-off after announcing uncertainty around reimbursement last quarter.
The company’s new growth plan aims to align resources to revenue growth initiatives, streamline the organization and optimize supply chain by consolidating production to support quality, scale and efficiency.
Inspire expects a total of $20 million to $25 million in pre-tax restructuring charges in connection with the first phase of the new strategy. That includes approximately $4 million to $5 million in employee-related costs, plus $16 million to $20 million in other expenses (non-cash in nature).
The company expects its actions to create approximately $30 million in annualized growth investment capacity. It expects to invest this capital in revenue growth initiatives. Inspire expects the majority of actions related to the restructuring to be completed in the third quarter, with all actions to be substantially complete by the end of 2026. It did not specify if the restructuring includes any job cuts, like the one recently announced at Boston Scientific.
The details on Inspire’s Q2 earnings results
The Minneapolis-based maker of implantable neuromodulation technology for treating obstructive sleep apnea (OSA) reported profits of $314,000. That equals 1¢ per share on sales of $200.6 million for the three months ended June 30, 2026.
Inspire Medical recorded a massive bottom-line gain, pulling out of the red on a sales decrease of 7.6%.
Adjusted to exclude one-time items, earnings per share came in at 14¢. That landed 39¢ ahead of expectations on Wall Street. Sales also came in ahead of the forecast as experts projected $194.6 million in revenue.
Inspire Medical increased its guidance for 2026. It now expects adjusted EPS to range between $1.05 and $1.45 for the full year. The company previously budged for between 75¢ and $1.25, which was a massive decrease from its initial guidance for the year. The new adjusted EPS outlook brings the company a little closer to the original range of $1.85 to $2.35. Inspire also expects sales between $835 million and $875 million, marking a $10 million rise at the back end.
Tim Herbert, chair and CEO of Inspire Medical Systems, said:
“Our second quarter results reflect the increased discipline and focus we are bringing to the business as we continue to support customers through the evolving coding and reimbursement environment and invest in the long-term adoption of Inspire therapy. We are also announcing a strategic growth plan designed to generate approximately $30 million of annualized growth investment capacity, which we intend to redeploy into targeted growth initiatives. We believe these actions will strengthen our operating foundation, sharpen our focus on the highest-return opportunities, and position Inspire for sustainable growth and long-term value creation.”
